March 25th, 2005 - Volume 27 - Issue 6
pp: 2-59

Combidex Probably Useful, ODAC Says, But Finds Clinical Trials Unconvincing, Inadequate

Fromer, Margot J.

Oncology Times. 27(6):7-8, March 25th, 2005.

(1) Combidex Probably Useful, But Clinical Trials Unconvincing, Inadequate; (2) Iressa Redux: Still No Survival Advantage, Does It Work or Does It Not? (3) Two Bisphosphonate Drugs Found to Cause Osteonecrosis of the Jaw: What Response Is Appropriate?

FDA Advisory Committee's COX-2 Action Seen as Good News for Gynecologic Cancer Research

Eastman, Peggy

Oncology Times. 27(6):14-15, March 25th, 2005.

The thought of using targeted agents such as COX-2 inhibitors with significantly fewer toxicities than most of the common chemotherapy agents in use has many gynecologic oncologists excited.

CLL: How Eradicating Minimal Residual Disease Extends Survival

Fogarty, Mary

Oncology Times. 27(6):19-21, March 25th, 2005.

(1) Eradicating Minimal Residual Disease Extends Survival; and (2) Anti-Bcl-2 Approach Improves Response to Fludarabine/Cyclophosphamide